Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05377606
Other study ID # MD-187-2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 23, 2021
Est. completion date May 8, 2023

Study information

Verified date August 2023
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rhegmatogenous retinal detachment (RRD) is the separation of the neurosensory retina from the retinal pigment epithelium caused by the presence of a break that leads to the passage of fluid from the vitreous cavity into the potential subretinal space. It is a sight threatening disease, affecting largely people 50 years or older, with an annual incidence varying between 6.3 and 17.9 people per 100,000 population, and is unfortunately increasing. Although other surgical options do exist for the repair of primary RRD, pars plana vitrectomy (PPV) has clear advantages and is certainly effective in the treatment of these patients. Several agents are used for intraocular tamponade following PPV for RRD. These agents are either silicone oil (SO) or gases like air, perfluoropropane (C3F8), sulfur hexafluoride (SF6), or perfluoroethane (C2F6). In addition to the complications uniquely peculiar to using SO, research has found out that a reduction in retinal sensitivity on microperimetry was greater in SO tamponade in comparison with gas, as well as poorer visual outcome, microvasculature damage and affection of retinal layers including ganglion cell complex (GCC) in the SO group. Even though many studies were done to compare between SO and intraocular gas tamponades with respect to many aspects, only one study compared the effects SO had on macular vasculature and anatomy in comparison with air and no study at all to date has compared the SO to SF6 gas in terms of retinal vascular changes, correlating them to thinning of GCC and macular sensitivity, which is precisely the main aim of the current study.


Description:

Rhegmatogenous retinal detachment (RRD) is the separation of the neurosensory retina from the retinal pigment epithelium (RPE) caused by the presence of a break that leads to the passage of fluid from the vitreous cavity into the potential subretinal space. It is a sight threatening disease, affecting largely people 50 years or older, with an annual incidence varying between 6.3 and 17.9 people per 100,000 population, and is unfortunately increasing. Although other surgical options do exist for the repair of primary RRD, viz. scleral buckling and pneumatic retinopexy, primary pars plana vitrectomy (PPV) has clear advantages and is certainly effective in the treatment of these patients, with a primary success rate of 85%, making it the leading management modality. Several agents are used for intraocular tamponade following PPV for RRD, in order to provide surface tension across the retinal breaks thus preventing the ingress once more of fluid into the subretinal space, giving time for the permanent seal provided by the retinopexy done whether photocoagulation or cryopexy. These agents are either silicone oil (SO) or gases like air, perfluoropropane (C3F8), sulfur hexafluoride (SF6), or perfluoroethane (C2F6). In addition to the complications uniquely peculiar to using SO, research has found out that a reduction in retinal sensitivity on microperimetry was greater in SO tamponade in comparison with gas, as well as poorer visual outcome, microvasculature damage and affection of retinal layers including ganglion cell complex (GCC) in the former group leading to the so-called Silicone Oil-Related Visual Loss (SORVL). Even though many studies were done to compare between SO and intraocular gas tamponades with respect to many aspects, only one study by Zhou et al in 2020 compared the effects SO endotamponade had on macular vasculature and anatomy in comparison with sterilized air tamponade and no study at all to date has compared the SO to SF6 gas in terms of retinal vascular changes, correlating them to thinning of GCC and macular sensitivity, which is precisely the main aim of the current study.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date May 8, 2023
Est. primary completion date March 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Primary rhegmatogenous retinal detachment Exclusion Criteria: - Macula-on retinal detachment - Change of decision of type of endotamponade used intraoperatively - Giant retinal tear - Proliferative vitreoretinopathy worse than grade B - Recent lens surgery within the previous 3 months prior to presentation - Prior vitreoretinal surgery - Macular hole - Signs of epiretinal membrane - Diabetic retinopathy - Macular degeneration or other macular disorders - Inferior retinal breaks between 4 and 8 o'clock - History of uveitis - History of glaucoma

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pars plana vitrectomy with silicone oil
Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
Pars plana vitrectomy with SF6
Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.

Locations

Country Name City State
Egypt Faculty of Medicine, Cairo University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (16)

Abrams GW, Azen SP, McCuen BW 2nd, Flynn HW Jr, Lai MY, Ryan SJ. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol. 1997 Mar;115(3):335-44. doi: 10.1001/archopht.1997.01100150337005. — View Citation

Barrie T. Debate overview. Repair of a primary rhegmatogenous retinal detachment. Br J Ophthalmol. 2003 Jun;87(6):790. doi: 10.1136/bjo.87.6.790. No abstract available. — View Citation

Christensen UC, la Cour M. Visual loss after use of intraocular silicone oil associated with thinning of inner retinal layers. Acta Ophthalmol. 2012 Dec;90(8):733-7. doi: 10.1111/j.1755-3768.2011.02248.x. Epub 2011 Sep 13. — View Citation

Goker YS, Yuksel K, Turan MF, Sonmez K, Tekin K, Yilmazbas P. Segmental Analysis of Macular Layers in Patients With Rhegmatogenous Retinal Detachment Treated With Perfluoropropane or Silicon Oil. Ophthalmic Surg Lasers Imaging Retina. 2018 Jan 1;49(1):41-47. doi: 10.3928/23258160-20171215-06. — View Citation

Hajari JN, Bjerrum SS, Christensen U, Kiilgaard JF, Bek T, la Cour M. A nationwide study on the incidence of rhegmatogenous retinal detachment in Denmark, with emphasis on the risk of the fellow eye. Retina. 2014 Aug;34(8):1658-65. doi: 10.1097/IAE.0000000000000104. — View Citation

Krzystolik MG, D'Amico DJ. Complications of intraocular tamponade: silicone oil versus intraocular gas. Int Ophthalmol Clin. 2000 Winter;40(1):187-200. doi: 10.1097/00004397-200040010-00018. No abstract available. — View Citation

Ma Y, Zhu XQ, Peng XY. Macular Perfusion Changes and Ganglion Cell Complex Loss in Patients with Silicone Oil-related Visual Loss. Biomed Environ Sci. 2020 Mar 20;33(3):151-157. doi: 10.3967/bes2020.021. — View Citation

Mitry D, Charteris DG, Fleck BW, Campbell H, Singh J. The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations. Br J Ophthalmol. 2010 Jun;94(6):678-84. doi: 10.1136/bjo.2009.157727. Epub 2009 Jun 9. — View Citation

Moharram HM, Abdelhalim AS, Hamid MA, Abdelkader MF. Comparison Between Silicone Oil and Gas in Tamponading Giant Retinal Breaks. Clin Ophthalmol. 2020 Jan 15;14:127-132. doi: 10.2147/OPTH.S237783. eCollection 2020. — View Citation

Newsom RS, Johnston R, Sullivan PM, Aylward GB, Holder GE, Gregor ZJ. Sudden visual loss after removal of silicone oil. Retina. 2004 Dec;24(6):871-7. doi: 10.1097/00006982-200412000-00005. — View Citation

Nielsen BR, Alberti M, Bjerrum SS, la Cour M. The incidence of rhegmatogenous retinal detachment is increasing. Acta Ophthalmol. 2020 Sep;98(6):603-606. doi: 10.1111/aos.14380. Epub 2020 Feb 21. — View Citation

Raczynska D, Mitrosz K, Raczynska K, Glasner L. The Influence of Silicone Oil on the Ganglion Cell Complex After Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment. Curr Pharm Des. 2018 Dec 8;24(29):3476-3493. doi: 10.2174/1381612824666180813115438. — View Citation

Scheerlinck LM, Schellekens PA, Liem AT, Steijns D, van Leeuwen R. Retinal sensitivity following intraocular silicone oil and gas tamponade for rhegmatogenous retinal detachment. Acta Ophthalmol. 2018 Sep;96(6):641-647. doi: 10.1111/aos.13685. Epub 2018 Mar 2. — View Citation

Schwartz SG, Flynn HW Jr, Wang X, Kuriyan AE, Abariga SA, Lee WH. Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. Cochrane Database Syst Rev. 2020 May 13;5(5):CD006126. doi: 10.1002/14651858.CD006126.pub4. — View Citation

Vaziri K, Schwartz SG, Kishor KS, Flynn HW Jr. Tamponade in the surgical management of retinal detachment. Clin Ophthalmol. 2016 Mar 16;10:471-6. doi: 10.2147/OPTH.S98529. eCollection 2016. — View Citation

Zhou Y, Zhang S, Zhou H, Gao M, Liu H, Sun X. Comparison of fundus changes following silicone oil and sterilized air tamponade for macular-on retinal detachment patients. BMC Ophthalmol. 2020 Jun 22;20(1):249. doi: 10.1186/s12886-020-01523-9. — View Citation

* Note: There are 16 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Macular perfusion - FAZ Comparison of foveal avascular zone area between the different treatment arms as a measure of macular perfusion. At 2 and 4 months following primary vitrectomy
Primary Macular perfusion - SVP Comparison of superficial retinal capillary vascular density between the different treatment arms. At 2 and 4 months following primary vitrectomy
Primary Macular perfusion - DVP Comparison of deep retinal capillary vascular density between the different treatment arms. At 2 and 4 months following primary vitrectomy
Secondary Macular sensitivity Comparison of macular sensitivity between the different treatment arms using macular microperimetry. At 2 and 4 months following primary vitrectomy
Secondary Thickness of ganglion cell complex Comparison of the thickness of ganglion cell complex in microns between the different treatment arms using optical coherence tomography (OCT) At 2 and 4 months following primary vitrectomy
Secondary Best corrected visual acuity Comparison of best corrected visual acuity between the different treatment arms using standard Snellen charts. At 2 and 4 months following primary vitrectomy
Secondary Retinal reattachment rate Comparison of single-operation anatomical success (retinal reattachment) rate between the different treatment arms At 4 months following primary vitrectomy
See also
  Status Clinical Trial Phase
Recruiting NCT04403750 - Combined Laser-surgical Technology of RRD Treatment N/A
Not yet recruiting NCT04520789 - Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy N/A
Recruiting NCT04571788 - Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle
Completed NCT02834559 - Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Phase 3
Recruiting NCT01845571 - Retinal Detachment - Demographic and Clinical Survey
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Recruiting NCT02871531 - Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria N/A
Completed NCT00757536 - Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment N/A
Active, not recruiting NCT00370201 - Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Phase 3
Completed NCT00345007 - Macular Function After Scleral Buckle N/A
Recruiting NCT05331664 - Dropless Pars Plana Vitrectomy Study Phase 4
Completed NCT02841306 - Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment Phase 1
Not yet recruiting NCT02185469 - Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment N/A
Not yet recruiting NCT01647373 - Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling N/A
Completed NCT01068379 - Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation Phase 3
Not yet recruiting NCT06468397 - Acute Retinal Detachment Repair With the iSeelr^TM Retinal Detachment Repair System N/A
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Recruiting NCT06056596 - Lamivudine and Plasma Markers of Inflammation in Retinal Detachment Early Phase 1
Completed NCT01343134 - Anatomical and Functional Macular Changes in Retinal Detachment N/A
Recruiting NCT05588037 - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery N/A